Having trouble accessing articles? Reset your cache.

Dapagliflozin regulatory update

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that Type II diabetes drug Forxiga dapagliflozin from Bristol-Myers Squibb and

Read the full 278 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE